Arch Therapeutics to Webcast Live From the Biotech Showcase Investor Conference

Arch Therapeutics to Webcast Live From the Biotech Showcase Investor Conference 
WELLESLEY, MA -- (Marketwired) -- 01/08/14 --  Arch Therapeutics,
Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company
and developer of AC5(TM), a novel product aimed at controlling
bleeding and fluid loss in order to provide faster and safer surgical
and interventional care, is pleased to announce that Terrence W.
Norchi, M.D., CEO of Arch Therapeutics will present at The Biotech
Showcase(TM) 2014 conference on Monday, January 13th, at 5:00PM PST.
Attendees will find the presentation scheduled for "Track C" in the
Mission II room at that time. Dr. Norchi's presentation will provide
insights into the Company's ongoing activities to commercially
develop novel technologies into a suite of new products targeting
markets of unmet clinical need. 
A live webcast of Dr. Norchi's Biotech Showcase presentation can be
accessed at the following URL:  
The Biotech Showcase(TM) 2014 Conference ( takes
place January 13-15, 2014 at the Parc 55 Wyndham Hotel, located at
Union Square, San Francisco, California. The Biotech Showcase(TM) is
an investor and partnering conference devoted to providing private
and public biotechnology and life sciences companies an opportunity
to present to, and meet with, investors and pharmaceutical executives
during the course of one of the industry's largest annual healthcare
investor conferences. Now in its sixth year, Biotech Showcase is
expected to attract upwards of 1,500 attendees. 
About Arch Therapeutics, Inc. (OTCQB: ARTH)
 Arch Therapeutics, Inc.
is a medical device company developing a novel approach to stop
bleeding (hemostasis) and control leaking (sealant) during surgery
and trauma care. Arch is developing products based on an innovative
self-assembling peptide technology platform to make surgery and
interventional care faster and safer for patients. Arch's flagship
development stage product candidate, known as AC5(TM), is being
designed to achieve hemostasis in minimally invasive and open
surgical procedures. Find out more at  
Notice Regarding Forward-Looking Statements
 This news release
contains "forward-looking statements" as that term is defined in
Section 27(a) of the Securities Act of 1933, as amended, and Section
21(e) of the Securities Exchange Act of 1934, as amended. Statements
in this press release that are not purely historical are
forward-looking statements and include any statements regarding
beliefs, plans, expectations or intentions regarding the future. Such
forward-looking statements include, among other things, references to
novel technologies and methods, our business and product development
plans and projections, or market information. Actual results could
differ from those projected in any forward-looking statements due to
numerous factors. Such factors include, among others, the inherent
uncertainties associated with developing new products or technologies
and operating as a development stage company, our ability to retain
important members of our management team and attract other qualified
personnel, our ability to raise the additional funding we will need
to continue to pursue our business and product development plans, our
ability to develop and commercialize products based on our technology
platform, and market conditions. These forward-looking statements are
made as of the date of this news release, and we assume no obligation
to update the forward-looking statements, or to update the reasons
why actual results could differ from those projected in the
forward-looking statements. Although we believe that any beliefs,
plans, expectations and intentions contained in this press release
are reasonable, there can be no assurance that any such beliefs,
plans, expectations or intentions will prove to be accurate.
Investors should consult all of the information set forth herein and
should also refer to the risk factors disclosure outlined in the
reports and other documents we file with the SEC, available at 
On Behalf of the Board,
 Terrence W. Norchi, MD.
 Arch Therapeutics,
ARTH Investor Relations
Toll Free: +1-855-340-ARTH (2784) (US and Canada)
Press spacebar to pause and continue. Press esc to stop.